Preemptive therapy versus universal prophylaxis: Time for reconciliation?

Affiliations

¹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
² Infectious Disease Service and Transplantation Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Editorial

Eleftheria Kampouri et al. Transpl Infect Dis. 2023 Apr.

. 2023 Apr;25(2):e14014.

doi: 10.1111/tid.14014. Epub 2023 Feb 3.

¹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
² Infectious Disease Service and Transplantation Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

No abstract available

References

1. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis. 2005;40(5):704-708. doi:10.1086/427506
1. Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900-931. doi:10.1097/TP.0000000000002191
1. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13512. doi:10.1111/ctr.13512
1. Singh N, Winston DJ, Razonable RR, et al. Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial. JAMA. 2020;323(14):1378-1387. doi:10.1001/jama.2020.3138
1. Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis. 2002;185(12):1723-1728. doi:10.1086/340653